European Journal Of Haematology · 2014 · 37 citations · 19 references
MedicineNuclear MedicineRadiologyDiagnostic ImagingDiagnostic RadiologyOncologic ImagingLymphoid TumorsLymphoma ImagingPositron Emission TomographyTumor CharacterizationFalse Positive FindingsLymphoid Neoplasm DiagnosisLymphoma StagingResidual Disease StagingResponse Capability AssessmentRestaging Of Lymphoma
UNLABELLED: Burkitt lymphoma (BL) is highly FDG-avid even though its usefulness in the management of these patients is still controversial. AIM: We analyzed the role of positron emission tomography/computerized tomography (PET/CT) in staging newly diagnosed patients with BL and evaluating disease after first-line chemotherapy. METHODS: Fifty-two PET/CTs were performed in 32 patients (20 at diagnosis, 27 after treatment, five to monitor residual disease). Involved areas were retrospectively compared with those observed in contrast-enhanced CT. RESULTS: Discrepancies were found in 64.7% of patients for whom results of both tests at diagnosis were available (n = 17), most of them involving extranodal sites. Regarding response assessment, discrepancies were observed in 38% of patients with both tests (5/13): residual masses detected by CT with negative PET/CT. Of 27 patients with post-treatment PET/CT, 22 were in complete remission whereas one true-positive and four false-positive lesions (two nodal and two extranodal) were detected. With a median follow-up of 27 months, 22 patients with negative PET/CT did not relapse. Thus, negative predictive value (NPV) was 100%. With respect to positive predictive value (PPV), one of five patients with positive assays after treatment died due to progression while the remaining four had false-positive lesions. Nevertheless, for these four patients, mean SUVmax at nodal sites was 4.1 vs. 14.9 at diagnosis, while mean SUVmax at extranodal sites was 3.8 vs. 12.1. Thus, with a cutoff value for SUVmax < 66% of that observed at diagnosis, PPV was also 100%. CONCLUSION: More accurate staging can be achieved using PET/CT. NPV reaches 100%, and using a ΔSUV < 66%, a high PPV is also observed.
19
Malik E. Juweid, Sigrid Stroobants, Otto S. Hoekstra et al. · Journal of Clinical Oncology · 2007 · 1.3K citations · Full text
Medicine, Nuclear Medicine, Oncology +16
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
H. Zhuang, Michael Pourdehnad, E.S. Lambright et al. · PubMed · 2001 · 622 citations
Medicine, Nuclear Medicine, Oncology +17